RxDoctor Payments Data

John McCarley, MD

Nephrology · Chattanooga, TNNPI 1760480321

Payments from drug & device makers

$1,847in general payments, 2019–2025

Across 99 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$266
  • AstraZeneca$261
  • Travere Therapeutics, Inc.$239
  • Vifor Pharma, Inc.$199
  • Amgen$151
  • Aurinia Pharma U.S., Inc.$131
  • plus $599 from 19 others

What the payments were for

  • Food & beverage$1,76295%
  • Education$845%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,847 in reported general payments places this provider in the 50th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$508,346
Medicare patients
1,013
Services billed
13,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$256,608
FarxigaDapagliflozin Propanediol59$65,132
KerendiaFinerenone14$21,501
JardianceEmpagliflozin14$14,046
Potassium Citrate ErPotassium Citrate27$4,889
Losartan Potassium131$1,957
Calcitriol81$1,220
Potassium Chloride49$1,008
Amlodipine Besylate145$858
Cinacalcet Hcl15$840
Torsemide55$837
Irbesartan40$774
Chlorthalidone35$728
Nifedipine ErNifedipine19$483
Spironolactone52$463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$266$256,60813 claims
AstraZenecaFarxiga$261$65,13259 claims
BayerKerendia$86$21,50114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →